Matches in SemOpenAlex for { <https://semopenalex.org/work/W2802683025> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W2802683025 abstract "Background Gabapentin and pregabalin are antiepileptic medications licensed for the treatment of neuropathic pain. The Department of Health has highlighted the need for vigilance when prescribing these medications due to their misuse and associated risks: dependency, CNS depression, seizure activity and mortality. Furthermore, due to the frequency of withdrawal symptoms, the manufacturers have recommended that pregabalin should be weaned gradually over a minimum of one week. Objectives To; Assess prescribing practices, frequency of misuse and frequency of serious adverse events in relation to gabapentin/pregabalin in the palliative care setting Methods An anonymous survey was designed and administered using SurveyMonkey. It was distributed via email link to palliative medicine physicians (PMPs) and palliative care nurse specialists (PCNSs) Results 49 responses were received- 36 from PMPs, 13 from PCNSs. 48/49 respondents prescribe or advise gabapentin/pregabalin. 94% of respondents prescribe pregabalin more frequently than gabapentin. When discontinuing gabapentin/pregabalin, 16% stop without weaning, 6% wean over three days, 20% wean over one week, 56% wean over one week or more. Seizure activity and respiratory depression secondary to gabapentin/pregabalin was reported by 6% (3/49) of respondents. 8% (4/49) of respondents reported that they suspected or believed some of their patients to have misused gabapentin/pregabalin- none reported their concerns to the UK Committee on the Safety of Medicines or the Health Products Regulatory Authority. Conclusions Gabapentin and pregabalin are commonly prescribed in palliative care, practices vary with regard to weaning the medications, and serious adverse events and misuse of these medications are occurring but are not being reported. Respondents displayed a growing awareness of the abuse potential of these medications in the comments section of the survey and report having modified their prescribing practices on account of this." @default.
- W2802683025 created "2018-05-17" @default.
- W2802683025 creator A5004660354 @default.
- W2802683025 creator A5059625438 @default.
- W2802683025 date "2018-03-01" @default.
- W2802683025 modified "2023-09-23" @default.
- W2802683025 title "26 Gabapentin and pregabalin use, misuse and associated risks in the palliative care setting" @default.
- W2802683025 doi "https://doi.org/10.1136/bmjspcare-2018-aspabstracts.53" @default.
- W2802683025 hasPublicationYear "2018" @default.
- W2802683025 type Work @default.
- W2802683025 sameAs 2802683025 @default.
- W2802683025 citedByCount "0" @default.
- W2802683025 crossrefType "proceedings-article" @default.
- W2802683025 hasAuthorship W2802683025A5004660354 @default.
- W2802683025 hasAuthorship W2802683025A5059625438 @default.
- W2802683025 hasBestOaLocation W28026830251 @default.
- W2802683025 hasConcept C142724271 @default.
- W2802683025 hasConcept C159110408 @default.
- W2802683025 hasConcept C177713679 @default.
- W2802683025 hasConcept C197934379 @default.
- W2802683025 hasConcept C204787440 @default.
- W2802683025 hasConcept C2776468701 @default.
- W2802683025 hasConcept C2776608144 @default.
- W2802683025 hasConcept C2777107010 @default.
- W2802683025 hasConcept C2994186709 @default.
- W2802683025 hasConcept C42219234 @default.
- W2802683025 hasConcept C71924100 @default.
- W2802683025 hasConcept C98274493 @default.
- W2802683025 hasConceptScore W2802683025C142724271 @default.
- W2802683025 hasConceptScore W2802683025C159110408 @default.
- W2802683025 hasConceptScore W2802683025C177713679 @default.
- W2802683025 hasConceptScore W2802683025C197934379 @default.
- W2802683025 hasConceptScore W2802683025C204787440 @default.
- W2802683025 hasConceptScore W2802683025C2776468701 @default.
- W2802683025 hasConceptScore W2802683025C2776608144 @default.
- W2802683025 hasConceptScore W2802683025C2777107010 @default.
- W2802683025 hasConceptScore W2802683025C2994186709 @default.
- W2802683025 hasConceptScore W2802683025C42219234 @default.
- W2802683025 hasConceptScore W2802683025C71924100 @default.
- W2802683025 hasConceptScore W2802683025C98274493 @default.
- W2802683025 hasLocation W28026830251 @default.
- W2802683025 hasLocation W28026830252 @default.
- W2802683025 hasOpenAccess W2802683025 @default.
- W2802683025 hasPrimaryLocation W28026830251 @default.
- W2802683025 hasRelatedWork W1905121086 @default.
- W2802683025 hasRelatedWork W1973025996 @default.
- W2802683025 hasRelatedWork W2000566189 @default.
- W2802683025 hasRelatedWork W2027521838 @default.
- W2802683025 hasRelatedWork W2055643091 @default.
- W2802683025 hasRelatedWork W2080114610 @default.
- W2802683025 hasRelatedWork W2090860211 @default.
- W2802683025 hasRelatedWork W2093439844 @default.
- W2802683025 hasRelatedWork W2143966410 @default.
- W2802683025 hasRelatedWork W2160521327 @default.
- W2802683025 hasRelatedWork W2896354100 @default.
- W2802683025 hasRelatedWork W2898251267 @default.
- W2802683025 hasRelatedWork W2973926613 @default.
- W2802683025 hasRelatedWork W3000813436 @default.
- W2802683025 hasRelatedWork W3006536476 @default.
- W2802683025 hasRelatedWork W3022271243 @default.
- W2802683025 hasRelatedWork W3049502768 @default.
- W2802683025 hasRelatedWork W3138823389 @default.
- W2802683025 hasRelatedWork W3162192988 @default.
- W2802683025 hasRelatedWork W3209423719 @default.
- W2802683025 isParatext "false" @default.
- W2802683025 isRetracted "false" @default.
- W2802683025 magId "2802683025" @default.
- W2802683025 workType "article" @default.